Across TCGA pan-cancer cohorts, SUMO2P4 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SUMO2P4’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where SUMO2P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SUMO2P4 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.
LUAD and LUSC are the cancer types where SUMO2P4 tumor–normal differential expression is most reproducible.